Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

2018; Elsevier BV; Volume: 30; Issue: 3 Linguagem: Inglês

10.1093/annonc/mdy517

ISSN

1569-8041

Autores

Sylvia Adams, P. Schmid, H. S. Rugo, EP Winer, D. Loirat, Ahmad Awada, D.W. Cescon, Hiromitsu Iwata, M. Campone, Rita Nanda, Rita L. Hui, Giuseppe Curigliano, D. Toppmeyer, Joyce O’Shaughnessy, Sherene Loi, Shani Paluch–Shimon, Antoinette R. Tan, Deborah Card, Jing Zhao, V. Karantza, Javier Cortés,

Tópico(s)

PARP inhibition in cancer therapy

Resumo

Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.

Referência(s)